Overview

Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will test the safety and efficacy of everolimus on heart transplant recipients. This study is not recruiting in the United States.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Everolimus
Sirolimus